Fosmidomycin, a novel chemotherapeutic agent for malaria.

Antimicrobial Agents and Chemotherapy
Bertrand LellPeter G Kremsner


In previous studies, fosmidomycin has been shown to possess activity against Plasmodium falciparum in vitro and in the mouse model. It has a novel mode of action through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase, an enzyme of the nonmevalonate pathway of isoprenoid biosynthesis, which is absent in humans. In this open-label, uncontrolled trial, the efficacy and safety of fosmidomycin, in an oral dose of 1,200 mg every 8 h for 7 days, were evaluated in the treatment of acute uncomplicated Plasmodium falciparum malaria in 20 adult subjects in Gabon and Thailand. Clinical assessments were performed and thick blood smears were evaluated every 8 h until parasite clearance and resolution of symptoms were achieved; assessments continued at weekly intervals thereafter for the duration of the 28-day followup period. All subjects were clinically and parasitologically cured on day 7 (primary end point). Parasite and fever clearance were rapid, with means of 44 and 41 h, respectively. On day 28, seven out of nine subjects (78%) were cured in Gabon and two out of nine subjects (22%) were cured in Thailand. The drug was well tolerated, although mild gastrointestinal side effects were recorded for five subjects. Analysis o...Continue Reading


Jan 1, 1976·Annual Review of Biochemistry·E D Beytía, J W Porter
Feb 1, 1989·The Journal of Antimicrobial Chemotherapy·P G KremsnerR M Rocha
Nov 1, 1971·The American Journal of Tropical Medicine and Hygiene·K H RieckmannP E Carson
Aug 6, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·J F KunP G Kremsner
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C HögenauerE C Reisinger
Jan 11, 2001·The Journal of Antimicrobial Chemotherapy·J WiströmB Svenungsson
Feb 24, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·E H SyllaP G Kremsner
Mar 30, 2001·Bioorganic & Medicinal Chemistry Letters·Armin ReichenbergHassan Jomaa


Aug 12, 2009·Applied Microbiology and Biotechnology·Remco MuntendamOliver Kayser
Sep 18, 2007·Journal of Computer-aided Molecular Design·Nidhi SinghChristopher R McCurdy
Jun 12, 2003·Bioorganic & Medicinal Chemistry Letters·Regina OrtmannMartin Schlitzer
Oct 27, 2011·Chemical Reviews·Cyrille Y BottéChristophe Biot
Jul 4, 2013·Journal of Medicinal Chemistry·Anna M JanssonSherry L Mowbray
Sep 3, 2005·Nature Reviews. Drug Discovery·Richard PinkMary Bendig
Apr 15, 2004·Nature Reviews. Microbiology·Stuart A RalphGeoffrey I McFadden
Jun 22, 2011·The Journal of Experimental Medicine·Sethu C NairBoris Striepen
Jan 28, 2012·Acta Crystallographica. Section D, Biological Crystallography·Christofer BjörkelidT Alwyn Jones
Jun 8, 2007·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Shunsuke YajimaHaruo Seto
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Steffen BorrmannPeter G Kremsner
Oct 25, 2006·Antimicrobial Agents and Chemotherapy·T N C RamyaAvadhesha Surolia
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Steffen BorrmannPeter G Kremsner
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Ravit Arav-Boger, Theresa A Shapiro
Sep 11, 2012·Malaria Journal·Melinda P AnthonyTimothy N C Wells
Nov 19, 2003·PLoS Biology·Vincent P Alibu, Thomas G Egwang
Nov 26, 2013·Journal of Industrial Microbiology & Biotechnology·Kou-San JuWilliam W Metcalf
Jul 31, 2007·Future Microbiology·Leann TilleyPatrick G Bray
Apr 14, 2010·Wiener klinische Wochenschrift·Peter G Kremsner
Jul 12, 2011·Cellular and Molecular Life Sciences : CMLS·Tobias GräwertWolfgang Eisenreich
Dec 13, 2012·Expert Opinion on Therapeutic Targets·Christopher D Goodman, Geoffrey I McFadden
Mar 11, 2005·Expert Opinion on Therapeutic Targets·Jochen Wiesner, Frank Seeber
Jan 1, 2008·Expert Review of Clinical Pharmacology·Andrew VallelyDaniel Chandramohan
Jan 8, 2015·Expert Opinion on Investigational Drugs·Jana HeldAndrea Kreidenweiss
Jul 20, 2012·Expert Opinion on Emerging Drugs·Serena TschanBenjamin Mordmüller
Sep 20, 2007·Expert Opinion on Drug Safety·Rana ChattopadhyaySanjai Kumar
Apr 13, 2010·Trends in Parasitology·Isabelle CoppensSean T Prigge
Feb 13, 2007·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Johannes KaiserA Golan-Goldhirsh
Oct 24, 2006·European Journal of Medicinal Chemistry·Katrin SchlüterThomas Kurz
Feb 23, 2012·Scientific Reports·Tomonobu UmedaKazuo T Nakamura
Feb 25, 2005·Biological Reviews of the Cambridge Philosophical Society·R J M Iain Wilson
Oct 29, 2003·Trends in Parasitology·Alan F Cowman, Brendan S Crabb
Oct 29, 2003·Trends in Parasitology·Giancarlo A BiaginiPatrick G Bray
Feb 26, 2008·Archiv der Pharmazie·Martin Schlitzer
Jul 6, 2007·Archiv der Pharmazie·Thomas KurzRolf D Walter

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.